Age-related changes in the gene expression profile of antigen-specific mouse CD8+ T cells can be partially reversed by blockade of the BTLA/CD160 pathways during vaccination

Dawany, Noor; Parzych, Elizabeth M.; Showe, Louise C.; Ertl, Hildegund C.J.

doi:10.18632/aging.101105

Cited by 3 publications

(3 citation statements)

References 41 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In xenograft, mouse models have verified that age is connected with changes in immune system [11, 12]. When compared with younger ones, older mice further proved modificative cytokine kinetics [13] and reduced CD8 + T cell proliferation [14], and this is also associated with the decrement in T cell function [15] and CD28 expression [16, 17], which is a co-stimulatory signal for T cell activation [18]. But in clinical trials, Elias et al [19] reviewed efficacy and safety of ICI in patients with non-small cell lung cancer, melanoma, and renal cancer and found that there were no obvious age-associated difference in overall survival (OS) and side effects among those older and younger patients.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis

Zhang

Sun

et al. 2019

BioMed Research International

View full text Add to dashboard Buy / Rent full text

Objectives. Despite the fact that it is widely acknowledged that immune checkpoint inhibitors (ICIs) rely on the presence of immune response to take their antitumor effect, little is known whether there is an influence exerted on the efficacy of ICIs based on patients’ age. We performed a systematic review and meta-analysis to explore the efficacy of ICIs between younger and older patients. Materials and Methods. We searched online database and major conference proceedings for randomized controlled trials (RCTs) published of ICIs and included RCTs that conducted subgroup comparisons of age with available combination of hazard ratios (HRs) and 95% confidence interval (95%CI). Subsequently, we figured out the pooled HR and 95%CI in younger and older patients with a random-effects model and evaluated the within-study heterogeneity by using subgroup, sensitivity, and meta-regression analysis. Results and Conclusion. A total of 12 eligible RCTs included in our study, which reported OS according to patients’ age. The overall estimated random-effects for HR was 0.75 with 95% CI of 0.65-0.87 in younger arm versus 0.81 with 95% CI of 0.72-0.92 in older arm. ICIs can improve OS for patients with advanced or metastatic lung cancer when compared to controls, especially for those patients with NSCLC, anti-PD-1/PD-L1 inhibitors, non-squamous, Pembrolizumab or Atezolizumab used as well as subsequent-line setting, and the magnitude of benefit in OS had comparable efficacy in both younger and older arms using a cut-off of 65 yr. Conversely, we also drew a statically significant conclusion that older patients failed to acquire benefit from ICIs when subdivided with a further cut-off of 75 yr.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis

Zhang

Sun

et al. 2019

BioMed Research International

View full text Add to dashboard Buy / Rent full text

show abstract

“…Such differences are in part associated with agedependent changes in the hormonal milieu, cytokine profile, and antigen-presenting cell responsiveness after immunization (54)(55)(56). Influenza nucleoprotein-based vaccine studies also indicate that aged mice have alterations in CD4 ϩ T-helper and CD8 ϩ cytotoxic T cell frequencies compared to young mice (57,58). Aged mice also require multiple doses of vaccines, higher quantities of antigen, or the addition of adjuvant to elicit improved immune responses and protective efficacy of influenza vaccines compared to young mice (59,60).…”

Section: Figmentioning

confidence: 99%

Host Factors Impact Vaccine Efficacy: Implications for Seasonal and Universal Influenza Vaccine Programs

Dhakal

Klein

2019

J Virol

View full text Add to dashboard Buy / Rent full text

Influenza is a global public health problem. Current seasonal influenza vaccines have highly variable efficacy, and thus attempts to develop broadly protective universal influenza vaccines with durable protection are under way. While much attention is given to the virus-related factors contributing to inconsistent vaccine responses, host-associated factors are often neglected. Growing evidences suggest that host factors including age, biological sex, pregnancy, and immune history play important roles as modifiers of influenza virus vaccine efficacy. We hypothesize that host genetics, the hormonal milieu, and gut microbiota contribute to host-related differences in influenza virus vaccine efficacy. This review highlights the current insights and future perspectives into host-specific factors that impact influenza vaccine-induced immunity and protection. Consideration of the host factors that affect influenza vaccine-induced immunity might improve influenza vaccines by providing empirical evidence for optimizing or even personalizing vaccine type, dose, and use of adjuvants for current seasonal and future universal influenza vaccines.

show abstract

“…In 2015, the BTLA-HVEM signaling pathway was reported to help intestinal parasites (especially Strongyloides stercoralis ) maintain an infection (26). In the following year, vaccines blocking the BTLA/CD160 signaling pathway were shown to activate the response of aged CD8 + T cells to the influenza virus (27). Moreover, dendritic cells (DCs) were demonstrated to induce extrathymic T-cell tolerance in peripheral Treg cells through the BTLA-HVEM signaling pathway (28).…”

Section: Chronological Milestones In Btla Researchmentioning

confidence: 99%

BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection

Zheng

Mao

et al. 2019

Front. Immunol.

View full text Add to dashboard Buy / Rent full text

B- and T-lymphocyte attenuator (BTLA) is an immune-regulatory receptor, similar to CTLA-4 and PD-1, and is mainly expressed on B-, T-, and all mature lymphocyte cells. Herpes virus entry mediator (HVEM)-BTLA plays a critical role in immune tolerance and immune responses which are areas of intense research. However, the mechanisms of the BTLA and the BTLA/HVEM signaling pathway in human diseases remain unclear. This review describes the research milestones of BTLA and HVEM in chronological order and their role in chronic HBV infection.

show abstract

Age-related changes in the gene expression profile of antigen-specific mouse CD8+ T cells can be partially reversed by blockade of the BTLA/CD160 pathways during vaccination

Cited by 3 publications

References 41 publications

Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis

Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis

Host Factors Impact Vaccine Efficacy: Implications for Seasonal and Universal Influenza Vaccine Programs

BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection

Contact Info

Product

Resources

About